Capability
Quantum Surgical: Strategic Analysis of Medical Robotics and European Sovereignty
How does the Epione robotic platform combine imaging, AI and robotics for percutaneous tumor ablation?
Quantum Surgical, a Montpellier-based French deep-tech firm founded in 2017, develops the Epione®. Defence-finance analysis; 15-page sourced DFM PDF report.
This public thread presents the concise analytical answer. The complete evidence, source base and assessment are available below.
Part of our Research, Universities & Deep Tech and Defence & Dual-Use Companies coverage →
Original DFM publication · DFM Analysis report · 2025-12-30
Quantum Surgical, a Montpellier-based French deep-tech firm founded in 2017, develops the Epione® robotic platform for minimally invasive tumor ablations . Combining medical imaging, AI, and robotics, Epione assists radiologists in planning and executing percutaneous needle ablations for tumors in the abdomen, chest, and musculoskeletal structures.
The company has rapidly commercialized its technology – it holds CE certification in Europe (covering liver, kidney, pancreas, lung, chest and bone cancers) and FDA clearance in the US for abdominal ablations .
This analysis answers: How does the Epione robotic platform combine imaging, AI and robotics for percutaneous tumor ablation? How mature is the technology given CE and FDA clearances across multiple cancer indications? What partners and markets support commercialisation of the Montpellier firm's medical robotics? What capability gaps and dependencies affect Quantum Surgical's dual-use/sovereignty positioning?
Choose how to continue
Go deeper on this question
Keep getting the analysis
DFM publishes new defence-finance analysis every week.
Original DFM analysis
Quantum Surgical: Strategic Analysis of Medical Robotics and European Sovereignty
The publication details above identify the source used for this public thread.
FAQ
What is Quantum Surgical: Strategic Analysis of Medical Robotics and European Sovereignty?
The company has rapidly commercialized its technology – it holds CE certification in Europe (covering liver, kidney, pancreas, lung, chest and bone cancers) and FDA clearance in the US for abdominal ablations .
Related DFM Platform threads
Explore this category Strategic Autonomy
Professional requests (internal interest signal — not a marketplace; nothing is charged or promised)
See Professional & Institutional Access — plans, group/institutional seats and contact →
Defence Finance Monitor is an analytical and informational product. It does not constitute investment advice, financial advice or a recommendation to buy or sell securities. Subscriptions run on DFM Analysis. Payments for Professional Packs are processed securely by Stripe at checkout.